Navigation Links
Study on PLC Systems' TMR Therapy With Stem Cells Presented at ESC 2009
Date:9/14/2009

one and millions more worldwide."

"The combination of CD133+ stem cell transplantation and surgical myocardial revascularization promises to be a new and enhanced causal therapy of severe ischemic cardiomyopathy," stated Dr. Klein. "Although the follow-up has not yet been completed, we can strongly suppose that this procedure significantly augments improvement in left ventricle function."

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard(R), is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that the final resul
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
4. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
10. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
11. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN -News).  ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Celladon and certain of its ... of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... , April 27, 2015 Kalorama Information ... medical records (EMR) to grow well past the ... providers, according to a recent report.  The healthcare ... sales and continued efficiency improvements will grow the ... the next five years.  The market for EMR ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
... , BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: ... ongoing Phase IIa study of narlaprevir (SCH 900518), its ... treatment-naive patients with chronic hepatitis C virus (HCV) genotype ... in which patients received a 4-week lead-in of PEGINTRON(R) ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8
(Date:4/27/2015)... (PRWEB) April 27, 2015 Array ... exchange technology, has announced that Lance Hood, senior director ... the fourth annual Direct-to-Consumer Health Care Marketing Summit ... by David Smith, Partner and Director of Payer Services, ... health care consumerism – through a retail/e-commerce perspective – ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Beckman Coulter ... Next-Gen sequencing to study the evolution of neural circuitry ... which will review the mechanisms by which analogous forms ... (LR) body flexions, evolved independently in certain sea slug ... be broadcast live April 30, 2015 at 8:00am PT. ...
(Date:4/27/2015)... The Doctors on Liens mission ... personal injury attorneys with the best doctors working on a ... growth throughout their history and that trend continues with the ... his team in the Tujunga / Sunland area. ... therapist, patients can find comprehensive care and detailed documentation of ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... aspiration holes and additional electrode tip ... precise dissection with decreased risk of ... ,Flexible design options allow the ... and multiple tip designs. Optimize specific ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: